Final-Program-ATS-2023-AP.vp

MONDAY • MAY 22

173

P213 ELEVATE 2: Baseline Demographic Characteristics From the Phase IIB Study of the Efficacy and Safety of Two Doses of Rodatristat Ethyl When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension/ A. Skride, Riga, Latvia P214 Extended Pulmonary Retention of Inhaled Liposomal Treprostinil (l606) Correlated With Pharmacodynamics and Plasma Pharmacokinetics/ P. Kan, Taipei, Taiwan P215 Dose-response Analyses of Treprostinil Inhalation Powder in PAH and Its Effect on 6MWD/ K. El-Kersh, Omaha, NE P216 Real-world Use of Upfront Combination Therapy in Pulmonary Arterial Hypertension (PAH) Patients/ C. Paoli, Titusville, NJ P217 Effectiveness and Safety of Riociguat as First-line or Combination Therapy in Pulmonary Arterial Hypertension (PAH): A Riociguat Users (ROAR) Registry Analysis/ R.J. White, Rochester, NY P218 Treprostinil Palmitil Hydrolysis Is Facilitated by Lung Esterases/ T.L. Nguyen, Bridgewater, NJ P219 RKER-012, a Novel Activin Receptor Type IIB (ActRIIB) Ligand Trap, Inhibited Mediators of Dysregulated Vascular Remodeling in Pulmonary Endothelial and Smooth Muscle Cells/ A. Gudelsky, Lexington, MA P220 The Influence of Route and Formulation on the Pulmonary Pharmacokinetics of Imatinib in Nonclinical Species/ R. Niven, Waltham, MA P221 ACE2 Treatment of Pulmonary Hypertension Requires the Mas1 Receptor, But Ang(1-7) Is Not the Ligand/ J.D. West, Nashville, TN

P224 17b-estradiol Prevents NLRP3 Activation and Contractile Dysfunction in Right Ventricles and Right Ventricle Cardiomyocytes From Rats With Pulmonary Hypertension/ R. Sobrano Fais, Denver, CO P225 The Critical Role of High Mobility Group Box1 (HMGB1) in Regulating the Sex-Specific P53 Signaling in Pulmonary Arterial Hypertension/ O.S. Lawal, Tucson, AZ P226 Genome-wide Association Analyses Identified Novel Susceptibility Loci for Pulmonary Embolism Among Han Chinese Population/ Z. Zhang, Beijing, China P227 Early Non-invasive Predictors of Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia in Preterm Infants/ R. Siddaiah, Hershey, PA P228 Quantitative Computed Tomography Lung Parenchymal Features Can Aid in Phenotyping of Group 1 and Group 3 Pulmonary Hypertension/ K. Dwivedi, Sheffield, United Kingdom P229 Response to Inhaled Iloprost Better Predicts Long-Term Survival Than Nitric Oxide in Patients With Pulmonary Hypertension: Results From the Prospective Ovation Study (nct03044314)/ R.A. Krasuski, Durham, NC P230 Associations Between Serum Activin A and Follistatine-Like 3 Levels and Outcomes in Pulmonary Arterial Hypertension/ C. Guignabert, Le Kremlin-Bicêtre, France P231 Extracellular Vesicles From in Vitro and in Vivo Models of Acute Lung Injury Induce Endothelial Dysfunction in Naïve Pulmonary Endothelial Cells/ B. Guarino, Providence, RI P232 Practices Affecting Opsumit ® and Uptravir ® atient Persistence Rates Utilizing Pulmonary Arterial Hypertension Clinical Site and Patient Perspectives: A US Qualitative Research Analysis (PERSIST)/ C. Mcevoy, St Louis, MO P233 Loss of GATA6 in Lung Endothelial Cells Leads to ER Stress/UPR and Contributes to PAH Pathogenesis/ V. Dambal, boston, MA P234 Coronavirus Disease Vaccination In Patients With Pulmonary Hypertension: A National Prospective Cohort Study/ X.-H. Wu, Beijing, China P235 Assessment of Thermodilution Versus Direct Fick Cardiac Output Among Patients With Pulmonary Hypertension/ A.J. Brownstein, Los Angeles, CA P236 Persistence and Predictors of Persistency for Pulmonary Arterial Hypertension (PAH) Patients on Selexipag in Canada: A Retrospective Claims Database Study/ E. Ibrahim, Toronto, Canada P237 Assessment of Right Ventricular Work in Precapillary Pulmonary Hypertension/ G. Csósza, Budapest, Hungary

BASIC • CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

B60

LIFE MOVES FAST! LATE BREAKERS IN PULMONARY HYPERTENSION

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion 12:15-1:15 authors will be present for discussionwith assigned facilitators. P223 Circulating Stem, Progenitor and Endothelial Cells and Their Relationship to Disease Severity in Pulmonary Arterial Hypertension (PAH)/ C. Johnson, Bethesda, MD

ATS 2023 • Washington, DC